Retina World Congress

Retina World Congress

Source:

Healio Interviews

Disclosures: Dagnon reports being chief operations officer for Outlook Therapeutics.
May 13, 2022
1 min watch
Save

VIDEO: Outlook Therapeutics updates intravitreal bevacizumab path toward commercialization

Source:

Healio Interviews

Disclosures: Dagnon reports being chief operations officer for Outlook Therapeutics.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress here, Terry Dagnon, chief operations officer for Outlook Therapeutics, discusses the latest update on ONS-5010 for the treatment of wet AMD.

ONS-5010 is a formulation of bevacizumab being developed for intravitreal injection for the treatment of wet age-related macular degeneration and other retinal diseases. Currently, bevacizumab for intravitreal injection must be compounded from IV bevacizumab.